AFT hits US approval target, triggers cash

AFT hits US approval target, triggers cash
Managing director Hartley Atkinson said Maxigesic was an effective alternative for the US$700 million of IV paracetamol sold each year. (Photo: supplied).
Dan Brunskill
The United States medical regulator has accepted an application for AFT Pharmaceuticals’ patented pain relief medicine, which if approved would open up a more than US$300 million market.The US Food and Drug Administration has formally received the application for Maxigesic IV, an intravenous form of AFT’s painkiller, which was filed in August this year.Filing with the FDA triggers milestone payments worth US$3.6m under a licensing deal with US partner Hikma Pharmaceuticals. This will be recognised in the first half of the current fi...

More Markets

Craigs downgrades Mainfreight to ‘neutral’
Markets

Craigs downgrades Mainfreight to ‘neutral’

It follows the company saying it had a rough start to the year.

Chatham Rock Phosphate draws auditor concern, director ups stake
Markets

Chatham Rock Phosphate draws auditor concern, director ups stake

A director ups his stake in Chatham Rock Phosphate as auditors express concern.

Bathurst vs Talley's: battling on
Markets Part 3

Bathurst vs Talley's: battling on

Bathurst turned back to Asian investors to raise capital this year.

Kiwibank's $500m capital hike fails to inspire
Markets

Kiwibank's $500m capital hike fails to inspire

Capital raise plans designed to help the bank grab market share from its Aussie rivals.